Kura Oncology, Inc. (NASDAQ:KURA) Shares Sold by KLP Kapitalforvaltning AS

KLP Kapitalforvaltning AS decreased its holdings in Kura Oncology, Inc. (NASDAQ:KURA) by 53.4% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,800 shares of the company’s stock after selling 7,800 shares during the quarter. KLP Kapitalforvaltning AS’s holdings in Kura Oncology were worth $45,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in KURA. Thrivent Financial for Lutherans purchased a new stake in Kura Oncology during the 4th quarter worth approximately $250,000. American Century Companies Inc. lifted its stake in shares of Kura Oncology by 101.6% during the fourth quarter. American Century Companies Inc. now owns 66,706 shares of the company’s stock worth $581,000 after buying an additional 33,612 shares during the period. Sei Investments Co. grew its holdings in shares of Kura Oncology by 41.0% during the fourth quarter. Sei Investments Co. now owns 20,815 shares of the company’s stock valued at $181,000 after buying an additional 6,055 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Kura Oncology by 14.6% in the 4th quarter. Vanguard Group Inc. now owns 4,818,898 shares of the company’s stock valued at $41,973,000 after acquiring an additional 615,211 shares during the period. Finally, Trexquant Investment LP increased its position in shares of Kura Oncology by 867.8% in the 4th quarter. Trexquant Investment LP now owns 566,945 shares of the company’s stock valued at $4,938,000 after acquiring an additional 508,362 shares during the period.

Analyst Ratings Changes

A number of brokerages have commented on KURA. JMP Securities reaffirmed a “market outperform” rating and set a $28.00 price target on shares of Kura Oncology in a research report on Wednesday, June 4th. HC Wainwright reaffirmed a “buy” rating and set a $40.00 target price on shares of Kura Oncology in a report on Monday, April 28th. Barclays cut their price target on shares of Kura Oncology from $32.00 to $11.00 and set an “overweight” rating on the stock in a report on Friday, May 2nd. Cantor Fitzgerald reissued an “overweight” rating on shares of Kura Oncology in a research report on Thursday, June 26th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $36.00 price objective on shares of Kura Oncology in a report on Friday, June 20th. Four investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $24.50.

Kura Oncology Stock Performance

KURA opened at $6.02 on Friday. The firm has a fifty day moving average price of $6.17 and a 200 day moving average price of $6.74. Kura Oncology, Inc. has a 1 year low of $5.41 and a 1 year high of $21.57. The stock has a market cap of $521.15 million, a P/E ratio of -2.87 and a beta of 0.41. The company has a debt-to-equity ratio of 0.02, a current ratio of 8.07 and a quick ratio of 8.07.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings data on Thursday, May 1st. The company reported ($0.66) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.15). The business had revenue of $14.11 million for the quarter, compared to analyst estimates of $39.08 million. Equities research analysts anticipate that Kura Oncology, Inc. will post -2.44 earnings per share for the current year.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.